drugset
drugset / Trial / NCT04990440

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT04990440 ↗

Phase 2 Terminated 6 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of Bermekimab, compared with placebo, in participants with moderate-to-severe atopic dermatitis (AD).

Timeline

Start
2021-09-02
Primary completion
2022-03-09
Completion
2022-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bermekimab Monoclonal antibody — Intravenous

Indications

atopic eczema